Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 15 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 9713635

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted Jul 25, 2017 · Expires Jul 20, 2037

    granted

  2. US 9700596

    Locally released growth factors to mediate motor recovery after stroke

    The Regents of the University of California · Granted Jul 11, 2017 · Expires Jul 6, 2037

    granted

  3. US 9695243

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Jul 4, 2017 · Expires Jun 29, 2037

    granted

  4. US 9687461

    Method for detecting risk factor for metabolic syndrome or hyperferritinemia

    United States of America as represented by the Secretary of the Air Force · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted

  5. US 9688987

    Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted

  6. US 9676779

    Small molecule CFTR correctors

    DISCOVERYBIOMED, INC. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

  7. US 9676846

    Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

  8. US 9675676

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

  9. US 9677062

    Hyaluronidase and factor VIII compositions

    HALOZYME, INC. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

  10. US 9669076

    Albumin-free factor VIII formulations

    UNIVERSITY OF CONNECTICUT · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted

  11. US 9670475

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted

  12. US 9670506

    Modified immunization vectors

    THE ARIZONA BOARD OF REGENTS · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted

  13. US 9663564

    Vectors and methods to treat ischemia

    The Regents of the University of California · Granted May 30, 2017 · Expires May 25, 2037

    granted

  14. US 9663485

    Tocopherol and tocopheryl quinone derivatives as correctors of Lysosomal Storage Disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 30, 2017 · Expires May 25, 2037

    granted

  15. US 9657096

    Human domain antibodies against components of the human insulin-like growth factor (IGF) system

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 23, 2017 · Expires May 18, 2037

    granted

  16. US 9657288

    Connector compound peptide phage display

    BICYCLE THERAPEUTICS LIMITED · Granted May 23, 2017 · Expires May 18, 2037

    granted

  17. US 9644216

    Adeno-associated virus vectors for treatment of glycogen storage disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 9, 2017 · Expires May 4, 2037

    granted

  18. US 9637524

    Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

    The Regents of the University of California · Granted May 2, 2017 · Expires Apr 27, 2037

    granted

  19. US 9629903

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Apr 25, 2017 · Expires Apr 20, 2037

    granted

  20. US 9623088

    Factor VIII polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  21. US 9623091

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  22. US 9624306

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  23. US 9622991

    Hematopoietic growth factor mimetic small molecule compounds and their uses

    Ligand Pharmaceuticals Incorporated · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  24. US 9598703

    Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH · Granted Mar 21, 2017 · Expires Mar 16, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.